98%
921
2 minutes
20
Objective: Atrial fibrillation (AF), if left untreated, is associated with increased intermediate and long-term morbidity/mortality. Surgical treatment for AF is lacking standardization in patient selection and lesion set, despite clear support from multi-society guidelines. The aim of this study was to analyze a statewide cardiac surgery registry to establish whether or not there is an association between center volume and type of index procedure with performance of surgical ablation (SA) for AF, the lesion set chosen, and ablation technology used.
Methods: Adult, first-time, nonemergency patients with preoperative AF between 2014 and 2022 excluding standalone SA procedures from a statewide registry of Society of Thoracic Surgeons data were included (N = 4320). AF treatment variability by hospital volume (ordered from smallest to largest) and surgery type were examined with χ analyses. Hospital-level Spearman correlations compared hospital volume with proportion of AF patients treated with SA.
Results: Overall, 37% of patients with AF were ablated at the time of surgery (63% of mitral procedures, 26% of non-mitrals) and 15% had left atrial appendage management only. There was a significant temporal trend of increasing performance of SA for AF over time (Cochran-Armitage = 27.8; P < .001). Hospital cardiac surgery volume did not correlate with the proportion of AF patients treated with SA (r = 0.19; P = .603) with a rate of SA below the state average for academic centers. Of cases with SA (n = 1582), only 43% had a biatrial lesion set. Procedures that involved mitral surgery were more likely to include a biatrial lesion set (χ = 392.3; P < .001) for both paroxysmal and persistent AF. Similarly, ablation technology use was variable by type of concomitant operation (χ = 219.0; P < .001) such that radiofrequency energy was more likely to be used in non-mitral procedures.
Conclusions: These results indicate an increase in adoption of SA for AF over time. No association between greater hospital volume or academic status and performance of SA for AF was established. Similar to national data, the type of index procedure remains the most consistent factor in the decision to perform SA with a disconnect between AF pathophysiology and decision making on the type of SA performed. This analysis demonstrates a gap between evidence-based guidelines and real-world practice, highlighting an opportunity to confer the benefits of concomitant SA to more patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jtcvs.2023.04.020 | DOI Listing |
Front Immunol
September 2025
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
NSG-SGM3 humanized mouse models are well-suited for studying human immune physiology but are technically challenging and expensive. We previously characterized a simplified NSG-SGM3 mouse, engrafted with human donor CD34 hematopoietic stem cells without receiving prior bone marrow ablation or human secondary lymphoid tissue implantation, that still retains human mast cell- and basophil-dependent passive anaphylaxis responses. Its capacities for human antibody production and human B cell maturation, however, remain unknown.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
E. Meshalkin National Medical Research Center, Institute of Cardiovascular Pathology Research, 630055 Novosibirsk, Russian Federation.
Background: Presently, the availability of single-stage surgical correction of mitral valve disease combined with atrial fibrillation (AF) via a mini-access approach remains limited. Moreover, the comparative effectiveness of this procedure versus conventional sternotomy (CS) remains poorly understood. Thus, this study aimed to conduct a comparative assessment of the efficacy and safety of concomitant mitral valve surgery and AF ablation via a minimally invasive approach (minimally invasive cardiac surgery, MICS group) versus the standard sternotomy approach (CS group).
View Article and Find Full Text PDFMed Phys
September 2025
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, P.R. China.
Background: In catheter-based radiofrequency ablation (RFA), energy is delivered to heterogeneous thin-walled tissues to induce therapeutic heating. Variations in electrical and mechanical properties of tissue contents have a great effect on outcomes.
Purpose: The objective of this study is to develop models that replicate tissue heterogeneity and visualize ablation zones for effective evaluation and optimization.
J Cardiovasc Electrophysiol
September 2025
Department of Cardiology, Stefan Cardinal Wyszynski Province Specialist Hospital, Lublin, Poland.
Introduction: Wave speed (WS) mapping, enabled by omnipolar technology, allows for real-time visualization of local conduction velocity (CV). Its utility in ventricular tachycardia (VT) ablation has not been fully characterized.
Methods And Results: We describe a case series of patients undergoing VT ablation in which WS mapping was applied alongside established techniques such as peak frequency (PF) mapping and isochronal late activation mapping (ILAM).
Br J Cancer
September 2025
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.
Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.